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Methodical approach to conducting a comprehensive 
pharmacoeconomic study of drug care in medical 
organizations
Irina V. Spichak, Yuliya S. Dereglazova*, Alyona S. Spichak, Elena V. Kaliuzhnaya
INTRODUCTION
The problem of rational pharmacotherapy in outpatient 
and inpatient therapy is one of the most significant to 
date, due to the occurrence and progression of most 
pathologies.[1-3] At present, there are separate methods 
for conducting pharmacoeconomic studies of drug 
care of various nosologies in the hospital or clinic, 
differing in a number of significant positions.[4-6] 
None of them allows conducting complex research, 
assessing the continuity of the pharmacotherapy 
process at each stage of drug assistance.[7,8]
The need for the formation of an integrated 
methodological approach is also due to the preferential 
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differences in the trends of medicinal prescriptions and 
the formation of the range of drugs for the treatment 
of various nosologies under outpatient and inpatient 
treatment.[9,10]
In this regard, it is important to develop a 
methodological approach to conducting a 
comprehensive pharmacoeconomic study of drug 
care in inpatient and outpatient settings of medical 
organizations (MO), assessing the continuity of 
treatment, the results of medical prescriptions, as well 
as the implementation of methodological, managerial, 
and economic support for pharmacotherapy.
MATERIALS AND METHODS
The methods of logical, system, graphical analyzes, the 
works of leading scientists in the field of management 
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and economics of pharmacy, and pharmaceutical 
production were used in this work.
RESULTS AND DISCUSSION
In the course of a large-scale study of drug assistance 
provided during pharmacotherapy in outpatient and 
inpatient conditions, a methodical approach was developed 
to conduct a comprehensive (hereinafter tandem) 
pharmacoeconomic study. The advantages of this approach 
are: The ability to study the sequence and continuity of 
treatment during outpatient treatment, and then inpatient 
treatment, identify trends in the formation of the range 
of drugs and conduct a comparative analysis, optimize 
the examination of drugs by specialists due to a clear 
distinction between the requirements for pharmacotherapy 
depending on the conditions of care, and, as a result, the 
formation of the most rational restrictive lists of drugs.
The main objective of comprehensive (hereinafter 
tandem) pharmacoeconomic study is to develop 
restrictive lists (formulary lists of drugs for stationary 
conditions and brand portfolios of drugs for 
outpatient) that are optimal according to the criteria 
“pharmacotherapeutic efficacy” – “characteristics 
of drugs” – “compliance with consumer 
expectations” – “price.”
The methodical approach provides for simultaneous 
and sequential execution and comparative analysis of 
the research stages: Formation of the database of the 
drugs; structural analysis of the drug assortment; ABC 
analysis of the drug assortment; multidimensional 
examination of the assortment; and regulatory cost 
analysis and determination of the drug budget of the 
inpatient department [Figure 1].
Within the framework of the methodological approach, 
the technology of multidimensional expertise of the 
drug assortment was developed for the first time, 
which implies a multi-stage, consistent assessment 
of the drug assortment conducted by pharmaceutical 
and medical experts according to a significant number 
of criteria. The technology of multidimensional 
expertise of the drug assortment helps to optimize the 
selection of drugs in restrictive lists and provides for 
the implementation of pharmaceutical evaluation of 
drugs from the point of view of their characteristics, 
VEN-expertise, analysis of compliance with consumer 
preferences, and evaluation of cost criteria [Figure 2].
The goal of a multidimensional examination of drugs 
assortment is the rationalization of drugs restrictive 
lists (official lists and brand portfolios).
1
stage
2
stage
3
stage
тап
4
stage
тап
5
stage
1
stage
2
stage
3
stage
4
stage
5
stage
6
stage
* - mainly for outpatient 
conditions
Doctors Pharmaceutical Specialists
Regulatory cost analysis and determination of the drug
budget of the medical organization departmentsComfort Standart Economy
Pharmaceutical Specialists
Analysis of the succession of 
prescription drugs
Development of formulary drug lists 
Pharmaceutical expertise of the 
range of drugs
Development of assortment lists of medicines 
in various price categories
VEN - expertise of the 
drug range
Estimation of cost 
criteria
Conformity assessment of drug
range according consumer 
criteria * *
ABC analysis of drug range
Comparative analysis of TOP - 10
positions
Analysis of compliance 
with the severity of the 
disease treatment 
continuity
Costs comparison
Identification of the irrationality 
of drug appointments
ABC analysis of drug range
Inpatient conditionsOutpatient conditions
Formation of information base of research
Structural analysis of drug range 
Formation of information base of research
Structural analysis of drug range 
Multidimensional examination of drug range 
Comprehensive pharmacoeconomic study of drug care in outpatient and inpatient conditions
Content - analysis of outpatient cards Content - analysis of case histories
Ranging the assortment of drugs by 
consumption groups
Ranging the assortment of drugs by 
consumption groups
Figure 1: Methodical approach of an integrated pharmacoeconomic study of drug care in medical organizations
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Conducting a multidimensional examination of drugs 
assortment involves the consistent participation 
of highly competent experts – pharmaceutical and 
medical specialists.
At the first stage, the highly competent pharmaceutical 
specialists (representatives of the MO formulary 
commission) implement the pharmaceutical expertise 
(PE) of the drug assortment. PE implies characteristics 
analyses of the drug range; selection of drugs that best 
meet the requirements of the examination; elimination 
of drugs that have limitations to the purpose and the 
formation of a summary of analytical information on 
the range for the preparation of expert doctors for the 
subsequent VEN-examination.
The technology of PE includes the sequential 
implementation of the following steps: Determination 
of the criteria for PE of the drugs range for specific 
conditions of analysis; analysis of the list of drugs 
characteristics, the choice and justification of the 
choice of their use under specific conditions of the 
study; identification of barrier (restrictive) drugs 
characteristics; removal of drugs from the expertise 
that does not fully meet the criteria; and the formation 
of information materials on the characteristics of the 
drugs to optimize VEN-expertise of the medicines 
range by doctors.
At the second stage, highly qualified medical 
specialists carry out VEN-expertise of the drug 
assortment with the purpose of segmenting the drug 
assortment, according to the optimality of the criter 
“pharmacotherapeutic efficacy” – “safety,” to justify 
the inclusion of the drug in restrictive lists. The 
purpose of the third stage is to analyze the assortment 
of pharmaceutical products for compliance with 
consumer preferences, which implies an assessment 
of the correspondence of the characteristics of 
pharmaceutical products to consumer criteria 
identified in the course of a sociological study of 
consumers of services. At the fourth and final stage, 
the evaluation of cost criteria is carried out through a 
comparative assessment of the cost of drugs and the 
cost of treatment (according to the results of the ABC 
analysis).
The methodical approach was tested in the course of 
a comprehensive pharmacoeconomic study of drug 
assistance to children with juvenile arthritis (JA) in 
the outpatient and inpatient conditions of children of 
the Belgorod Region MOs.
At the initial stage of the study, a content analysis was 
conducted of 900 case histories of children with JA – 
hospital patients and 86 outpatient cards – polyclinic 
patients. The analysis revealed the diagnosis of 2 
types of JA: Juvenile chronic arthritis and reactive 
arthritis (ReA), as a result of which further research 
under stationary conditions was conducted on these 
nosological forms of JA.
We have formed an information collection of drugs 
which amounted to 72 trade names, 48 international 
non-proprietary names, 2575 drug packages for 
ambulatory institutions and 106 trade names, 78 
international non-proprietary names and 1565 drug 
packages for hospitals.
We have identified the structure of the range and 
consumption of drugs for the treatment of these 
nosologies which are mainly formed at the expense of 
six groups according to the ATC classification, among 
them dominate: “Agents affecting the digestive system 
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Figure 2: Stages of a multidimensional examination of the range of drugs
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and metabolism;” “Agents affecting the musculoskeletal 
system;” “Hormones of systemic action,” etc.
At the same time, during the implementation of 
a detailed intragroup analysis implemented with 
the help of rheumatologists and pediatricians, we 
identified individual cases of irrationality in the 
prescription of a number of drugs, in particular, 
therapeutic polypharmacy, prescription of drugs that 
have limitations for use in childhood, etc. Further, 
an analysis was conducted on the compliance of the 
outpatient range with consumer characteristics. With 
the help of expert doctors, discrepancies between 
prescriptions of medicines on pharmacotherapeutic 
efficacy were revealed (25.7%); security (67%); and 
ease of use of drugs (37.7%). Analysis by the criterion 
of “affordable price of drugs” showed that every 
third prescribed drug is expensive. Then, using the 
ABC analysis, the drug assortment was segmented 
according to the frequency of prescription and the cost 
of treatment. Thus, it was revealed that in stationary 
conditions, the high consumption Group “A” for the 
treatment of JA takes 22.05% in the total range of the 
product, formed by drugs with a range of prescription 
rates (PR) from 17.4 to 2.3 and includes 15 drugs – 
Diclofenac, Meloxicam, Metipred, Sulfasalazine, 
and others. The average consumption Group “B” 
(22%) is formed by 15 drugs with PR from 2.1 to 
0.3 – Diprospan, Voltaren, Methotrexate, and others. 
The low consumption Group “C” (54.4%) includes 38 
drugs with PR of 0.3 and below – Nexium, Movalis, 
Indomethacin, etc.
At the next stage, we first implemented the technology 
of multidimensional expertise of the drug assortment. 
Thus, at the first stage, the inpatient and outpatient 
assortment is analyzed in detail – 80 and 72 drugs for 
the treatment of JA, respectively, from the viewpoint 
of their characteristics. For the examination, 19 drug 
characteristics were identified, while only 57% are 
reflected in the “Instructions for Use.”
In the course of the analysis, in particular, it was 
established that more than 90% of all medicines 
have no infant dosage and only 30% of them have 
the possibility of dividing while minimizing the risk 
to the child’s body. Only 6% of preparations have a 
children’s dosage form. It was revealed that 67% of the 
outpatient drug assortment is prescribed; however, in 8 
out of 10 cases they were asked to go to the pharmacy 
without a documented prescription. According to the 
results of the pharmaceutical examination, about 20% 
of medicinal drugs with limitations to the purpose 
were removed from the range. Analytical information 
materials on the characteristics of the selected 
assortment preparations for the preparation of expert 
doctors for VEN-expertise have also been formed.
At the next stage, we carried out a VEN-examination 
with the aim of segmenting the drug of the investigated 
range for the treatment of JA according to the degree 
of clinical significance, economic feasibility, and 
compliance with consumer criteria. Forty-seven highly 
qualified expert doctors – specialists from children’s 
hospitals and polyclinics of Belgorod, Kursk and other 
cities of Russia took part in the examination. The 
average coefficient of expert competence was 0.85. 
Based on the weighted average estimates obtained, 
the drug assortment was segmented into major drugs 
(V), essential, or substitution drugs (E), and secondary 
(inexpedient) (N) drugs. Hence, in particular, 20 drugs 
are combined in the “V” group: Movalis (in tablets), 
Voltaren (solution for in.), Sulfasalazine (in tablets), 
Calcium – D3-Nicomed (in tablets), etc.; in Group 
“E” – 21 drugs: Dolgit (gel), Diprospan (solution 
for in), etc.; and in the Group “N” – 36 drugs: 
Magnesium orotate (in tablets) and Metamizole 
sodium (solution for in), etc.
At the final stage, we developed five indicative lists of 
drugs for the treatment of children suffering from ReA, 
associated urogenic, enterogenic, and nasopharyngeal 
infections; polyarticular and oligoarticular arthritis 
in stationary conditions. Three assortment portfolios 
of drugs for the treatment of children with juvenile 
poly/oligoarticular arthritis on an outpatient basis — 
high-cost (“Comfort”); average cost (“Standard”); and 
low cost (“Economy”) for a course of treatment for 
1 month.
The developed brand portfolios and formulary lists 
were introduced into the activities of the Health 
Department of the Belgorod Region and the nurseries 
of the city of Belgorod, as evidenced by 8 acts of 
implementation.
CONCLUSION
1. Using the approaches of rational pharmaceutical 
management, a methodical approach was proposed 
to conduct a comprehensive pharmacoeconomic 
study of drug assistance to children simultaneously 
in outpatient and inpatient conditions, allowing 
to evaluate the continuity of treatment, the 
tendency of assortment formation to rationalize the 
subsequent development of restrictive drug lists. 
The approach involves the parallel implementation 
and comparative analysis of the following stages: 
The formation of an information base on drugs; 
structural analysis of the range of drugs; ABC 
analysis of the range; multidimensional examination 
of the range of drugs; the formation of restrictive 
lists of drugs for the treatment of children in 
outpatient and inpatient settings; regulatory cost 
analysis and determination of the drug budget of 
the inpatient department;
Irina V. Spichak, et al.
2399Drug Invention Today | Vol 11 • Issue 10 • 2019
2. Conducting a comprehensive pharmacoeconomic 
study allows us to solve a number of issues: 
To carry out a comparative analysis of the 
range of drugs prescribed for outpatient and 
inpatient treatment, taking into account the 
sequence and continuity of treatment; to conduct 
a multidimensional examination of drugs with 
the involvement of specialists of different profiles 
(pharmaceutical specialists, doctors); and to involve 
in the examination of drugs high-skilled ambulatory 
and inpatient specialists to differentiate drugs 
according to the conditions of medical care; develop 
restrictive lists of drugs that best comply with the 
principles of rational pharmacotherapy in outpatient 
and inpatient settings.
3. In the framework of the methodological approach, 
we first developed a technology for multidimensional 
examination of the drug assortment, which implies 
a multi-stage, consistent evaluation of the drug 
assortment, which is carried out by pharmaceutical 
and medical specialists, including four steps: 
PE from the position of their characteristics, 
VEN-expertise of the drug assortment, analysis 
of compliance with consumer preferences, and 
evaluation of cost criteria;
4. We also carried out an approbation of the 
methodological approach in the course of 
optimization of drug assistance to children with 
JA in the outpatient and inpatient conditions of 
children’s MOs in the Belgorod Region;
5. As a result of the study, we developed: Five indicative 
drug lists for treating children with arthritis in 
stationary conditions; three assortment portfolios of 
drug for the treatment of children with juvenile poly/
oligoarticular arthritis on an outpatient basis.
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